Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases

Abstract

The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.

1 . A method of treating and/or preventing a polyglutamine disease comprising administering a precursor of propionyl-CoA in an amount effective for treating and/or preventing a polyglutamine disease. 
   
   
       2 . The method according to  claim 1 , wherein the polyglutamine disease is Huntington disease. 
   
   
       3 . The method according to  claim 1 , wherein the precursor of propionyl-CoA is selected from the group consisting of odd-medium-chain fatty acids, seven-carbon fatty acid, triheptanoin, heptanoate, C5 ketone bodies, 3-ketovalerate and 3-hydroxyvalerate. 
   
   
       4 . The method according to  claim 1 , wherein the precursor of propionyl-CoA is triheptanoin, heptanoic acid or heptanoate. 
   
   
       5 . The method according to  claim 1 , wherein the precursor of propionyl-CoA is triheptanoin. 
   
   
       6 . The method according to  claim 1 , wherein the precursor of propionyl-CoA is administered via ingestion of a food substance containing said precursor. 
   
   
       7 . The method according to  claim 2 , wherein the precursor of propionyl-CoA is selected from the group consisting of odd-medium-chain fatty acids, seven-carbon fatty acid, triheptanoin, heptanoate, C5 ketone bodies, 3-ketovalerate and 3-hydroxyvalerate. 
   
   
       8 . The method according to  claim 2 , wherein the precursor of propionyl-CoA is triheptanoin, heptanoic acid or heptanoate. 
   
   
       9 . The method according to  claim 3 , wherein the precursor of propionyl-CoA is triheptanoin, heptanoic acid or heptanoate. 
   
   
       10 . The method according to  claim 7 , wherein the precursor of propionyl-CoA is triheptanoin, heptanoic acid or heptanoate. 
   
   
       11 . The method according to  claim 2 , wherein the precursor of propionyl-CoA is triheptanoin. 
   
   
       12 . The method according to  claim 3 , wherein the precursor of propionyl-CoA is triheptanoin. 
   
   
       13 . The method according to  claim 4 , wherein the precursor of propionyl-CoA is triheptanoin. 
   
   
       14 . The method according  claim 2 , wherein the precursor of propionyl-CoA is administered via ingestion of a food substance containing said precursor. 
   
   
       15 . The method according to  claim 3 , wherein the precursor of propionyl-CoA is administered via ingestion of a food substance containing said precursor. 
   
   
       16 . The method according to  claim 4 , wherein the precursor of propionyl-CoA is administered via ingestion of a food substance containing said precursor.